Lyra Therapeutics Q2 EPS $(0.74) Misses $(0.33) Estimate, Sales $598.00K Beat $350.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lyra Therapeutics (NASDAQ:LYRA) reported Q2 earnings per share (EPS) of $(0.74), missing the analyst estimate of $(0.33) by 124.24%. However, the company reported sales of $598K, beating the estimate of $350K by 70.86%.
August 14, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lyra Therapeutics reported a significant miss on EPS but a strong beat on sales. The EPS miss may concern investors, but the sales beat could provide some optimism.
The significant miss on EPS is likely to weigh on the stock price negatively, but the strong sales beat could mitigate some of the downside. Overall, the impact is mixed, leading to a neutral short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100